API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
22
PharmaCompass offers a list of Sitagliptin Phosphate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Sitagliptin Phosphate manufacturer or Sitagliptin Phosphate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Sitagliptin Phosphate manufacturer or Sitagliptin Phosphate supplier.
PharmaCompass also assists you with knowing the Sitagliptin Phosphate API Price utilized in the formulation of products. Sitagliptin Phosphate API Price is not always fixed or binding as the Sitagliptin Phosphate Price is obtained through a variety of data sources. The Sitagliptin Phosphate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A sitagliptin phosphate anhydrous manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of sitagliptin phosphate anhydrous, including repackagers and relabelers. The FDA regulates sitagliptin phosphate anhydrous manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. sitagliptin phosphate anhydrous API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of sitagliptin phosphate anhydrous manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A sitagliptin phosphate anhydrous supplier is an individual or a company that provides sitagliptin phosphate anhydrous active pharmaceutical ingredient (API) or sitagliptin phosphate anhydrous finished formulations upon request. The sitagliptin phosphate anhydrous suppliers may include sitagliptin phosphate anhydrous API manufacturers, exporters, distributors and traders.
click here to find a list of sitagliptin phosphate anhydrous suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A sitagliptin phosphate anhydrous DMF (Drug Master File) is a document detailing the whole manufacturing process of sitagliptin phosphate anhydrous active pharmaceutical ingredient (API) in detail. Different forms of sitagliptin phosphate anhydrous DMFs exist exist since differing nations have different regulations, such as sitagliptin phosphate anhydrous USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A sitagliptin phosphate anhydrous DMF submitted to regulatory agencies in the US is known as a USDMF. sitagliptin phosphate anhydrous USDMF includes data on sitagliptin phosphate anhydrous's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The sitagliptin phosphate anhydrous USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of sitagliptin phosphate anhydrous suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The sitagliptin phosphate anhydrous Drug Master File in Japan (sitagliptin phosphate anhydrous JDMF) empowers sitagliptin phosphate anhydrous API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the sitagliptin phosphate anhydrous JDMF during the approval evaluation for pharmaceutical products. At the time of sitagliptin phosphate anhydrous JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of sitagliptin phosphate anhydrous suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a sitagliptin phosphate anhydrous Drug Master File in Korea (sitagliptin phosphate anhydrous KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of sitagliptin phosphate anhydrous. The MFDS reviews the sitagliptin phosphate anhydrous KDMF as part of the drug registration process and uses the information provided in the sitagliptin phosphate anhydrous KDMF to evaluate the safety and efficacy of the drug.
After submitting a sitagliptin phosphate anhydrous KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their sitagliptin phosphate anhydrous API can apply through the Korea Drug Master File (KDMF).
click here to find a list of sitagliptin phosphate anhydrous suppliers with KDMF on PharmaCompass.
A sitagliptin phosphate anhydrous CEP of the European Pharmacopoeia monograph is often referred to as a sitagliptin phosphate anhydrous Certificate of Suitability (COS). The purpose of a sitagliptin phosphate anhydrous CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of sitagliptin phosphate anhydrous EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of sitagliptin phosphate anhydrous to their clients by showing that a sitagliptin phosphate anhydrous CEP has been issued for it. The manufacturer submits a sitagliptin phosphate anhydrous CEP (COS) as part of the market authorization procedure, and it takes on the role of a sitagliptin phosphate anhydrous CEP holder for the record. Additionally, the data presented in the sitagliptin phosphate anhydrous CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the sitagliptin phosphate anhydrous DMF.
A sitagliptin phosphate anhydrous CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. sitagliptin phosphate anhydrous CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of sitagliptin phosphate anhydrous suppliers with CEP (COS) on PharmaCompass.
A sitagliptin phosphate anhydrous written confirmation (sitagliptin phosphate anhydrous WC) is an official document issued by a regulatory agency to a sitagliptin phosphate anhydrous manufacturer, verifying that the manufacturing facility of a sitagliptin phosphate anhydrous active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting sitagliptin phosphate anhydrous APIs or sitagliptin phosphate anhydrous finished pharmaceutical products to another nation, regulatory agencies frequently require a sitagliptin phosphate anhydrous WC (written confirmation) as part of the regulatory process.
click here to find a list of sitagliptin phosphate anhydrous suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing sitagliptin phosphate anhydrous as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for sitagliptin phosphate anhydrous API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture sitagliptin phosphate anhydrous as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain sitagliptin phosphate anhydrous and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a sitagliptin phosphate anhydrous NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of sitagliptin phosphate anhydrous suppliers with NDC on PharmaCompass.
sitagliptin phosphate anhydrous Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of sitagliptin phosphate anhydrous GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right sitagliptin phosphate anhydrous GMP manufacturer or sitagliptin phosphate anhydrous GMP API supplier for your needs.
A sitagliptin phosphate anhydrous CoA (Certificate of Analysis) is a formal document that attests to sitagliptin phosphate anhydrous's compliance with sitagliptin phosphate anhydrous specifications and serves as a tool for batch-level quality control.
sitagliptin phosphate anhydrous CoA mostly includes findings from lab analyses of a specific batch. For each sitagliptin phosphate anhydrous CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
sitagliptin phosphate anhydrous may be tested according to a variety of international standards, such as European Pharmacopoeia (sitagliptin phosphate anhydrous EP), sitagliptin phosphate anhydrous JP (Japanese Pharmacopeia) and the US Pharmacopoeia (sitagliptin phosphate anhydrous USP).